IDENTIFICATION OF LIVER CYTOCHROME ENZYMES INVOLVEMENT IN LINCOMYCIN METABOLISM IN GOAT

IDENTIFICATION OF LIVER CYTOCHROME ENZYMES INVOLVEMENT IN LINCOMYCIN METABOLISM IN GOAT

Title: IDENTIFICATION OF LIVER CYTOCHROME ENZYMES INVOLVEMENT IN LINCOMYCIN METABOLISM IN GOAT

Authors: V Manoja, MK Lonare, Chandra Bhadra, R Kaur and SPS Saini

Source: Ruminant Science (2018)-7(2):217-214.

Cite this reference as: Manoja V, Lonare MK, Bhadra Chandra, Kaur R and Saini SPS (2018). Identification of liver cytochrome enzymes involvement in lincomycin metabolism in goat. Ruminant Science 7(2):217-214.

Abstract

Present study was planned to see the involvement of liver CYP isoenzymes in lincomycin metabolism in goats and kinetic analysis under in vitro system. Liver S9 fraction was prepared and in-vitro metabolism-kinetics of lincomycin was performed by adding lincomycin (50 µg.ml-1). The total protein and cytochrome P450 content was estimated 23.74± 0.9 mg/g of wet tissue and 0.56±0.10 nmol/mg of protein, respectively. Exposure of licomycin with S9 fraction of goat caused a decrease in lincomycin concentrations in time dependant manner. Kinetic parameter such as Km and Vmax was found to be 27.02 µg and 0.18 nM/min/mg of protein, respectively. Other parameters, in vitro elimination half life (t1/2)and intrinsic clearance (CLint) of was measured as 46.47±7.23 min and 5.68±0.91 mL/min/g, respectively. 65% of lincomycin was metabolized within 1 hour by S9 fraction. Drug metabolism inhibition study showed that participation CYP 1A2, 3A4, 2C9 and 2D6 enzymes in reaction do not alters the rate of lincomycin metabolism. Present study concluded that the tested hepatic liver isoenzymes do not play any role in licomycin metabolism in goats.

References

Baranczewski P, Stañczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P and Postlind H (2006). Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacological Reports 58:453-72.

Burrows GE, Brto PB, Martin B and Tripp ML (1983). Comparative pharmacokinetics of antibiotics in new born calves: Chloramphenicol, lincomycin and tylosin. American Journal of Veterinary Research 44:1053-57.

Collignon P, Courvalin P and Aidara-Kane A (2008). Clinical importance of antimicrobial drugs in human health. Guide to Antimicrobial Use in Animals. Blackwell Publishing, UK. pp 44-58.

Eberts FS, Meeks RC and Vliek RW (1963). Status report: Metabolism of 3H-Lincomycin in the Dog. Upjohn Company Inter Office Memo. p 17.

Goseline RE, Barbiers AR, Subacz CJ and Smith LJ (1978). 14C-Lincomycin(U-10, 149A) fate study in chickens. Upjohn Technical Report.

Gouri SS, Venkatachalam D and Dumka VK (2014). Pharmacokinetics of lincomycin following single intravenous administration in buffalo calves. Tropical Animal Health and Production 46:1099-1102.

Hornish RE, Arnold TS, Cox TD, Hubbard VI, Nappier JM, Pierce PA, Reeves DR, Stahl GI, Subacz CJ and Zaya MJ (1987). Lincomycin residues in the tissues of pig treated with 14C-lincomycin hydrochloride by feed additive at 20, 40, 100, and 200 grams per ton. Upjohn Technical Report 768-9760-87-001.

Houston JB (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemistry and Pharmacology 47:1469-1479

Houston JB and Kenworthy KE (1999). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition 28:246-54

Jia L and Liu X (2007). The conduct of drug metabolism studies considered good practice (II): In vitro experiments. Current Drug Metabolism 8:822-29.

Kleckner MD (1984). Lincomycin. In: Handbook Series in Zoonoses. Eds: JH Steele and GW Beran, Vol. I. CRC Press, Boca Rotan, FL. pp 337-345.

Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951). Protein measurement with the Folin phenol reagent. Journal of Biology and Chemistry 193:265-75.

Masengu C, Zimba F, Mangoyi R and Mukanganyama S (2014). Inhibitory activity of Combretumzeyheri and its S9 metabolites against E. coli, B. subtilis and Candida albicans. Journal of Microbiology and Biochemical Technology 6:228-35.

McLure JA, Miners JO and  Birkett DJ (2000). Nonspecific binding of drugs to human liver microsomes. British Journal of Clinical Pharmacology 49:453-461.

Sharma Meemansha, Vemu Bhaskar and Dumka VK (2017). Pharmacokinetics of lincomycin following intravenous administration in healthy goats. Ruminant Science 6(2):279-282.

Nielsen P and Gyrd-Hansen N (1998). Bioavailibility of lincomycin after oral administration to fed and fasted pigs. Journal of Veterinary Pharmacology and Therapeutic 21:251-56.

Omura T and Sato R (1964). The carbon monoxide binding pigment of liver microsomes. I. Evidence forits hemoprotein nature. Journal of Biology and Chemistry 239:2370-78.

Pioneau T, Gultier P, Bonfils C, Derancourt J and Maurel P (1990). Purification of sheep liver cytochrome form the P450111A gene family: Its contribution to N-dealklation of Veterinary drugs. Biochemical Pharmacology 39(5):901-909.

Rane A, Wilkinson GR and Shand DG (1977). Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics 200:420-424.

Rodrigues AD (1997). Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharmacology Research 14:1504-1510.

Spizek J and Rezanka T (2004). Lincomycin, cultivation of producing strains and biosynthesis. Applied Microbiology and Biotechnology 63:510-9.

Wen X and Walle T (2006). Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica 36:387-97.

Wisniewski JA, Moody DE, Hammock BD and Shull LR (1987). Interlobular distribution of hepatic xenobiotic-metabolizing enzyme activities in cattle, goats and sheep. Journal of Animal Science 64:210-15.